CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 136 enrolled
Drug / intervention
clexane (LMWH)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02856295
NCT02856295Phase 4Completed
CompareCT.gov

anti10a Levels in Women Treated With LMWH in the Postpartum Period for Preventing Vein Thrombosis Events: A Comparison of Two Doses

HaEmek Medical Center, Israel·interventional·Posted Aug 4, 2016·Updated Nov 15, 2022

In Brief

A Phase 4 clinical trial evaluating clexane (LMWH) for Venous Thromboembolism. Completed, enrolled 136 participants across 1 site.

Detailed Summary

The aim of this study is to compare between anti-10a levels in postpartum women receiving different prophylactic doses of LMWH: one group with LMWH doses adjusted by the women's weight and the second group receiving 1mg/kg to a maximum dose of 120 mg

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVenous Thromboembolism
CountriesIsrael
Collaborators--

Timeline

Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 4, 2016
Enrollment StartNov 20, 2021
Primary CompletionAug 1, 2022
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 9.9 years ago

Interventions

clexane (LMWH)drug

to compare tow doses of clexane for preventing VTE in postpartum women